Table 2.
MQTLs associated with multiple disease resistance identified in this study
| MQTL | Flanking markers (CI, in cM) | Number of QTLs (avg. LOD) | Disease (avg. PVE) |
|---|---|---|---|
| (a) MQTLs conferring resistance to 4 or more diseases | |||
| MQTL2B.2 | RAC875_rep_c109471_154/Xwmc25 (57.59–58.48) | 6 (6.98) | STB, FHB, KB, LS, SNB (20.8) |
| MQTL3B.1 | 3,955,846/M21/P76.3 (2.22–3) | 5 (8.47) | SNB, FHB, KB, STB (15.57) |
| MQTL3B.2 | XksuG53/4989073 (14.79–15.07) | 6 (6.99) | SNB, STB, FHB, KB (17.19) |
| (b) MQTLs conferring resistance to 3 diseases | |||
| MQTL1A.1 | RAC875_c16820_419/wsnp_Ra_c26191_35761997 (32.98–37.6) | 4 (4.25) | STB, SNB, FHB (5.78) |
| MQTL1B.4 | Kukri_c147_1620/cfa2129b (66.86–68.86) | 4 (8.7) | STB, LS, FHB (12.42) |
| MQTL2A.1 | wPt-9793/AX-94570860 (5.67–13.19) | 5 (3.96) | FHB, SNB, STB (7.86) |
| MQTL2D.3 | Xfba88/Xfba4 (39.55–39.85) | 3 (5.12) | STB, FHB, SNB (10.43) |
| MQTL3B.3 | Xgwm566/Xwmc762 (61.18–76.49) | 3 (5.17) | FHB, SNB, STB (9.1) |
| MQTL4A.1 | Excalibur_c56041_728/wsnp_BE403710B_Ta_2_1 (1.08–3.07) | 5 (12.36) | FHB, STB, KB (33.14) |
| MQTL4B.3 | BS00081631_51/Tdurum_contig64772_417 (111.89–115.45) | 4 (14.15) | STB, FHB, SNB (19.15) |
| MQTL5B.3 | XP7152-196/AX-110438459 (54.06–55.86) | 3 (4.9) | KB, FHB, STB (12.33) |